Nifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar to nicardipine. Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972. Since nifedipine's development, second and third generation dihydropyridines have been developed with slower onsets and lo...
Nifedipine capsules are indicated to treat vasospastic angina and chronic stable angina. Extended release tablets are indicated to treat vasospastic angina, chronic stable angina, and hypertension.
Marshall Obstetrics and Gynecology, Huntington, West Virginia, United States
Hasan Ali Inal, Antalya, Turkey
Columbia University Irving Medical Center, New York, New York, United States
Maternal Hypertension Center at Cabell Huntington Hospital, Huntington, West Virginia, United States
Alex Ekwueme Federal University Teaching Hospital, Abakaliki, Ebonyi, Nigeria
Himalayan Rescue Association, Kathmandu, Nepal
Trousseau University Hospital, Paris, France
Foothills Medical Centre, Calgary, Alberta, Canada
South Health Campus, Calgary, Alberta, Canada
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.